The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
29 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,405,195 in first-year total cost, median $192,240.
Most frequent study sections
- Special Emphasis Panel[ZCA1 RTRB-R (J1)]12
- Special Emphasis Panel[ZCA1 RTRB-R (O1)]9
- Special Emphasis Panel[ZCA1 RTRB-R (M1)]8
Most frequent institutions
- OHIO STATE UNIVERSITY2
- UNIV OF MASSACHUSETTS MED SCH WORCESTER2
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- WASHINGTON UNIVERSITY2
- WEILL MEDICAL COLL OF CORNELL UNIV2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Deciphering the Immune Evasion Mechanisms in Mutant IDH1 Cancer1K22CA288784-01A1 | WU, MENG-JU | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $196,029 | ZCA1 |
| 2025 | The role of GATA2 in myeloid malignancies and MonoMAC syndrome1K22CA285837-01 | KATERNDAHL, CASEY DUNCAN SAUL | INDIANA UNIVERSITY INDIANAPOLIS, IN | $194,688 | ZCA1 |
| 2025 | Chimeric Antigen Receptor Modified Natural Killer Cells for the Treatment of Solid Tumors1K22CA292567-01A1 | CHOCKLEY, PETER JAMES | OHIO STATE UNIVERSITY, OH | $192,564 | ZCA1 |
| 2025 | Unraveling the functional contribution of extracellular vesicles in pancreatic cancer1K22CA276360-01 | MCANDREWS, KATHLEEN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $192,240 | ZCA1 |
| 2025 | Etiology and Tumor Characteristics of Early-onset Pancreatic Cancer1K22CA288914-01 | YUAN, CHEN | CEDARS-SINAI MEDICAL CENTER, CA | $191,700 | ZCA1 |
| 2025 | Resolving viral oncoprotein control of terminal cell fates to limit Epstein-Barr virus-driven lymphoproliferation1K22CA288946-01 | SORELLE, ELLIOTT DANIEL | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $183,044 | ZCA1 |
| 2025 | The role of genetic and epigenetic variation in the progression of IDH mutant gliomas1K22CA285824-01 | WU, JINGYI | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $169,884 | ZCA1 |
| 2025 | Unraveling the Role of Microenvironmental Chemokines in Beta-Catenin/TCF Signaling and Gene Occupancy during Colorectal Cancer Metastasis to the Liver and Lung1K22CA288802-01A1 | RENNHACK, JONATHAN | LOYOLA UNIVERSITY CHICAGO, IL | $157,980 | ZCA1 |
| 2025 | The oncogenic roles of alarmins and monocytes in triple negative myelofibrosis1K22CA292451-01 | VINCELETTE, NICOLE | H. LEE MOFFITT CANCER CTR & RES INST, FL | $157,248 | ZCA1 |
| 2024 | New Proteomics Approaches to Study the Full Human Kinome, Inhibitor Resistance, and Kinase Degraders1K22CA282268-01 | YU, QING | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $211,918 | ZCA1 |
| 2024 | Targeting drivers of tumor heterogeneity to block the progression to neuroendocrine prostate cancer1K22CA269707-01A1 | BRADY, NICHOLAS JAMES | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $196,745 | ZCA1 |
| 2024 | Cancer Misinformation and Use of Complementary and Alternative Therapy (CAM) among Patients with Cancer.1K22CA288932-01 | FRIDMAN, ILONA | HACKENSACK UNIVERSITY MEDICAL CENTER, NJ | $194,400 | ZCA1 |
| 2024 | Investigating the cell intrinsic and extrinsic mechanisms governing lung cancer cell plasticity1K22CA289207-01 | YANG, DIAN | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $194,292 | ZCA1 |
| 2024 | Mechanisms of NK cell activation and immune-editing of leukemia1K22CA282364-01 | FOLTZ-STRINGFELLOW, JENNIFER ANN | WASHINGTON UNIVERSITY, MO | $193,797 | ZCA1 |
| 2024 | Investigating the mechanism of K17-mediated immunosuppression in papillomavirus-induced cancers1K22CA282264-01A1 | WANG, WEI | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES, MI | $193,616 | ZCA1 |
| 2024 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics1K22CA279077-01 | GU, SHENGQING | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $192,240 | ZCA1 |
| 2024 | Oncoprotein-regulated lineage plasticity in acute leukemia1K22CA272912-01A1 | JANSSENS, DEREK HENRY | VAN ANDEL RESEARCH INSTITUTE, MI | $192,240 | ZCA1 |
| 2024 | Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumor1K22CA276357-01 | ZHANG, HUA | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $189,756 | ZCA1 |
| 2024 | Elucidating Mechanisms of CAR ML NK cell biology to treat cancer and infection1K22CA279495-01 | ELLIOTT, MELISSA BERRIEN | SAINT LOUIS UNIVERSITY, MO | $186,030 | ZCA1 |
| 2024 | Targeting mitochondrial oxygen demand to overcome hypoxic immune privilege of NSCLC tumors1K22CA282363-01A1 | BENEJ, MARTIN | OHIO STATE UNIVERSITY, OH | $183,398 | ZCA1 |
| 2024 | Boosting IL-12-induced anti-glioblastoma activity via immunotherapeutic extracellular vesicles.1K22CA282019-01 | BREYNE, KOEN | MASSACHUSETTS GENERAL HOSPITAL, MA | $160,537 | ZCA1 |
| 2023 | Mechanisms and strategies to rescue suboptimal T cell priming in colon cancer1K22CA279501-01 | WESTCOTT, PETER MAXWELL KIENITZ | COLD SPRING HARBOR LABORATORY, NY | $201,042 | ZCA1 |
| 2023 | Augmenting cancer checkpoint immunotherapies via microbially-derived metabolites1K22CA272915-01 | GRIFFIN, MATTHEW EVERETT | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $198,018 | ZCA1 |
| 2023 | Defining the epigenetic landscape and therapeutic vulnerabilities of Richter's syndrome in CRISPR-based mouse models1K22CA269556-01 | TEN HACKEN, ELISA | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $196,020 | ZCA1 |
| 2023 | Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer1K22CA266737-01A1 | ANDERSON, KRISTIN GAIL | UNIVERSITY OF VIRGINIA, VA | $192,240 | ZCA1 |
| 2023 | Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer1K22CA276632-01 | WATERS, ANDREW M | UNIVERSITY OF CINCINNATI, OH | $191,864 | ZCA1 |
| 2023 | Revealing the cis-Regulatory Function of IMiDs in Multiple Myeloma”.1K22CA266739-01A1 | BARWICK, BENJAMIN GABRIEL | EMORY UNIVERSITY, GA | $187,448 | ZCA1 |
| 2023 | Role of Gut-Immune Interactions in Aging-Associated Bladder Cancer1K22CA270075-01 | WOOLBRIGHT, BENJAMIN LELAND | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $162,000 | ZCA1 |
| 2023 | Examining the Role of RNF168 Activity in BRCA1 Mutant Cancers1K22CA276631-01 | KRAIS, JOHN | WASHINGTON UNIVERSITY, MO | $152,217 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.